Gene Editing to Cross-Species Transplantation: The Most Compelling Healthcare Stories of 2022

01/24/23 • 37 min

In our first podcast episode of 2023, Back Bay’s strategic advisors summarize some of the most compelling healthcare development stories from 2022. From CRISPR and gene editing advancement to cross-species organ transplantation and the latest in the evolving regulatory and reimbursement landscape, these stories captivated us and continue to herald progress in health and human care.

Podcast experts include Brendan Wang, Christian Thienel and Peter Bak, with special thanks to Micheka Fenelon.

Podcast experts include Brendan Wang, Christian Thienel and Peter Bak, with special thanks to Micheka Fenelon.

Previous Episode

Preparing BioPharma and Medtech Companies for Public Listing - Back Bay Life Science Advisors and Nasdaq Nordic

For biopharma and medtech companies, the decision to go public is predicated on many business decisions—what kind of capital can be raised? Is our investor base strong and interested? Is now the right time? The Nordic Markets offer some distinct advantages at the earlier stage, and also offer new possibilities for US companies to list abroad. And although the specific logistical and mechanical aspects are exceedingly important, at the end of the day, the decision to do something like this is predicated on an amalgam of strategic decisions.

In this episode Back Bay Life Science Advisors and Nasdaq outline best practices for companies considering a public listing, including:

Steps in best practice strategy in an increasingly complex market
Advantages of listing with a smaller listing threshold market
Similarities and differences between Nasdaq US and Nasdaq Nordic markets
The strategic change and new dual listing option for US companies
The unique way retail participation makes up a large portion of the Nasdaq Nordic market (>25% of trades come in from retail)
Differences in support for emerging companies, Nordic v. US markets

Jonathan Gertler is CEO of Back Bay Life Science Advisors and Managing Partner at Bioventures Medtech Funds. Maria Groschopp Dellwik is Nasdaq’s Head of Strategy and Business Development for Global Listing Services in the Nordics, where she manages new offerings and key strategic change initiatives to improve listing offerings and the Swedish capital market.

Download “Preparing for a Public Listing: Best Practices for Biopharma, Medtech and
Healthtech Companies” from Back Bay Life Science Advisors and Nasdaq
https://bblsa.com/investment-banking-1

Next Episode

Contingencies for Biopharma, Medtech Deal Planning in a Down Market

For biopharma and medtech companies developing new treatments, capital for advancement and growth is invariably dependent on strategic preparation, differentiation, and persistence. Good preparation can mean funding or famine in a retracted market—and ultimately can impact the trajectory of a company and whether treatment reaches people in the clinical setting.

In a down market, there are creative and thoughtful approaches companies can take to stand out as capital becomes more closely guarded and the competition becomes fierce.

In this episode of Back Bay’s industry podcast, the Life Science Report, Jonathan Gertler speaks with Goodwin Procter life science partner Kristopher Brown about the current market landscape and how life science companies can recalibrate and prepare for capital raises—no matter the market outlook.

This episode focuses on discussion of deal management in the current market, including:

The current deal scape—difficult times ahead or par for the course in the life science sector?
Approaches to deal preparation in a challenging environment
Tentative M&A, licensing, partnering activity and public markets necessitate preparation and strategic focus ahead of capital raise, particularly:
- Thorough knowledge of asset differentiation - positioning, competitive intensity, pricing, milestone development/definition and valuation, among other activities
Creative deal financing models – royalty monetization, tranced investments, debt financing, preferred stock, liquidation preferences
Structure and valuation discipline
Portfolio and selection management toward a deal, including the use of AI in population identification

Find the video podcast and contribute to the conversation on Back Bay’s website: www.bblsa.com/podcasts